Loading
Clovis Oncology
Clovis Oncology was the Colorado company that brought the PARP inhibitor rucaparib (Rubraca) to market for ovarian and prostate cancer before filing for bankruptcy in December 2022; its products passed to pharma& in 2023.
Also called: Clovis Oncology, Inc.
Overview
Clovis Oncology, based in Boulder, Colorado and listed on Nasdaq, developed rucaparib (Rubraca), a PARP inhibitor approved in the United States from 2016 for BRCA-mutated ovarian cancer, then as maintenance therapy (ARIEL3) and for BRCA-mutated metastatic castration-resistant prostate cancer (TRITON2). An earlier lead, the EGFR inhibitor rociletinib, was abandoned in 2016 after disputed response data. Competition from other PARP inhibitors and a restricted label left the company unable to service its debt; it filed for Chapter 11 in December 2022 and sold Rubraca to pharma& in 2023. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Boulder, CO, US
Scorecard
All companies#168of 1245 companies, score 34
- approved products +6
- targets +4
- modalities +2
- regions +4
- 24-month regulatory events +4
- registry trials +14
1 approved, 0 in phase 3, 0 earlier, 2 targets, 49 registry studies. Formula on the scorecards page.
Type
Stage
Wound down
Website
Products
1ApprovedSmall-molecule PARP inhibitor
Rucaparib · Rubraca
Rucaparib is a DNA-repair inhibitor for selected BRCA-mutated ovarian and prostate cancers. Its prostate indication received regular US approval in December 2025.
Key papers
2rctNew England Journal of Medicine 2023changed practice374 citations
TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer
The randomised proof for PARP inhibition in BRCA-altered prostate cancer, and the clearest evidence that the homologous recombination repair gene list should not be used as a single yes-or-no test. ATM-altered disease needs a different answer, and does not yet have one.
rctJournal of Clinical Oncology 2020changed practice561 citations
TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration
The trial behind the second PARP inhibitor licensed in prostate cancer, and the evidence that a somatic BRCA alteration predicts response as well as an inherited one. Together with TOPARP-A it is why tumour as well as germline sequencing is recommended in metastatic disease.
Connected
11Similar pages
- TermWho is eligible for a PARP inhibitor in prostate cancer, and why the gene matters
Shares TRITON3, Rucaparib, PARP, Prostate cancer.
- TrialRucaparib with radiation after incomplete response to chemotherapy
- Key paperPROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations
Shares TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer, TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration, PARP, Prostate cancer.
- TreatmentDSB2455
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialStudy to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialA Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Shares PARP, Ovarian cancer, Prostate cancer.
- TrialPhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Shares PARP, Ovarian cancer, Prostate cancer.
cancers
fronts
targets
drugs
ApprovedSmall-molecule PARP inhibitor
Rucaparib · Rubraca
companies
trials
key papers
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Add official websites to 15 sponsor records and fetch nin… · diff · file
Sourced, not expert-reviewed